MedTrace Logo

Growth Hormone in the Treatment of HIV-Associated Wasting

NCT00489528 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-10-22

No results posted yet for this study

Summary

The purpose of this study is to compare physical function and lean body mass in patients getting different doses of somatropin compared to patients not getting the drug.

Conditions

  • HIV Infections
  • HIV Wasting Syndrome

Interventions

DRUG

Somatropin; Recombinant human growth hormone (r hGH)

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Svanbert, MD, PhD

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-07-31
Completion
2002-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00489528 on ClinicalTrials.gov